Figure 3
Selection of (Rap) 2 -E1-(Rap) 2 for TNBC. The potency of (Rap)2-E1-(Rap)2 was compared: A, with five non-Trop-2-targeting DNL-Rap conjugates in MDA-MB-468 and BT-20; B, with Rap(Q)-hRS7 in BT-20 and HCC1806; and C, with (Rap)2-E1*-(Rap)2 in HCC1806 and MDA-MB-468. (Rap)2-C2ā(Rap)2, (Rap)2-14-(Rap)2, (Rap)2-20-(Rap)2, (Rap)2-22-(Rap)2, and (Rap)2-74-(Rap)2 are five counterparts of (Rap)2-E1-(Rap)2, generated by substituting hRS7 with humanized antibodies that targets HLA-DR, CEACAM5, CD20, CD22, and CD74, respectively.